BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, November 9, 2025
See today's BioWorld MedTech
Home
» Staar sale to Alcon eclipsed by shareholder, proxy advisor concerns
To read the full story,
subscribe
or
sign in
.
Staar sale to Alcon eclipsed by shareholder, proxy advisor concerns
Oct. 16, 2025
By
Holland Johnson
ISS became the third proxy advisory firm to recommend shareholders vote against the proposed sale of Staar Surgical Co. to Alcon AG, joining Glass, Lewis & Co. LLC and Egan-Jones Ratings Co.
BioWorld MedTech
Deals and M&A
Ophthalmic
U.S.